- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020
- Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020
PR Newswire
SAN DIEGO, Aug. 5, 2020